Kymera Therapeutics Inc (KYMR) concluded trading on Thursday at a closing price of $25.97, with 0.47 million shares of worth about $12.17 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -42.03% during that period and on April 17, 2025 the price saw a gain of about 3.80%. Currently the company’s common shares owned by public are about 64.89M shares, out of which, 53.88M shares are available for trading.
Stock saw a price change of 15.94% in past 5 days and over the past one month there was a price change of -23.32%. Year-to-date (YTD), KYMR shares are showing a performance of -35.45% which decreased to -23.46% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $19.44 but also hit the highest price of $53.27 during that period. The average intraday trading volume for Kymera Therapeutics Inc shares is 677.88K. The stock is currently trading -1.70% below its 20-day simple moving average (SMA20), while that difference is down -16.90% for SMA50 and it goes to -36.55% lower than SMA200.
Kymera Therapeutics Inc (NASDAQ: KYMR) currently have 64.89M outstanding shares and institutions hold larger chunk of about 95.05% of that.
The stock has a current market capitalization of $1.69B and its 3Y-monthly beta is at 2.20. It has posted earnings per share of -$2.97 in the same period. It has Quick Ratio of 7.53 while making debt-to-equity ratio of 0.11. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for KYMR, volatility over the week remained 6.51% while standing at 9.08% over the month.
Stock’s fiscal year EPS is expected to drop by -24.05% while it is estimated to decrease by -11.51% in next year. EPS is likely to grow at an annualized rate of -10.89% for next 5-years, compared to annual growth of -26.36% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Citigroup on March 13, 2025 offering a Buy rating for the stock and assigned a target price of $52 to it. Coverage by BTIG Research stated Kymera Therapeutics Inc (KYMR) stock as a Buy in their note to investors on December 10, 2024, suggesting a price target of $60 for the stock. On December 06, 2024, BMO Capital Markets Initiated their recommendations, while on December 02, 2024, Wells Fargo Upgrade their ratings for the stock with a price target of $57. Stock get an Overweight rating from Stephens on November 18, 2024.
